Personalized blood pressure after stroke could boost recovery

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age ≥ 18 years； * Clinical diagnosis of acute ischemic stroke caused by anterior circulation large vessel occlusion (internal carotid artery or M1/M2 segment of the middle cerebral artery)； * Received EVT (including direct EVT and bridging therapy) within 24 hours of symptom onset； * Baseline ASPECTS score ≥ 3； * Baseline NIHSS score ≥ 6； * Successful recanalization achieved post-procedure (defined as expanded Thrombolysis in Cerebral Infarction \[eTICI\] grade ≥ 2b50); * Two consecutive systolic blood pressure (SBP) measurements ≥ 150 mmHg within 3 hours post-recanalization (with a measurement interval of no less than 5 minutes)； * Able to complete randomization within 3 hours post-recanalization； * Informed consent signed by the patient or their legal representative. Exclusion Criteria: * Pre-stroke mRS score \> 1； * Comatose state (Glasgow Coma Scale \[GCS\] score \< 8); * Symptomatic intracerebral hemorrhage occurred before randomization; * Within the past 3 months, occurrence of acute ST-segment elevation myocardial infarction (MI), acute decompensated heart failure, QTc \> 500 ms, hospitalization or involuntary coronary intervention due to acute coronary syndrome, MI, or cardiac arrest; or heart failure (New York Heart Association \[NYHA\] class III/IV or left ventricular ejection fraction \< 35%); or known history of ventricular tachycardia; * History of severe renal insufficiency, acute renal failure, dialysis, or estimated glomerular filtration rate (eGFR) \< 20 ml/min/1.72m²; * History of severe hepatic disease, or Aspartate Aminotransferase (AST) and/or Alanine Aminotransferase (ALT) and/or Gamma-Glutamyl Transferase (GGT) ≥ 3×ULN and/or Total Bilirubin (TBIL) ≥ 2×ULN; * Aortic dissection, cervical artery dissection, or cerebral artery dissection; unruptured aortic aneurysm or cerebral aneurysm; or known arteriovenous malformation; * Comorbidities with a life expectancy \< 6 months (e.g., malignant tumors); * Pregnant or lactating women; * Participation in another clinical trial within the past 30 days; * Any clinical condition judged by the research team that might limit compliance with study procedures.